Spravato generated $573 million in net sales in 2023 [1]. This figure represents a 25% increase compared to 2022 sales [1].
How is Spravato's Market Performance Evolving?
Spravato's sales growth in 2023 was primarily driven by an increase in its use for treatment-resistant depression and its expanded indication for depressive symptoms associated with bipolar depression [1]. The company projects continued growth in the coming years, with an anticipated $1 billion in sales by 2026 [2].
What is Spravato and How Does it Work?
Spravato, chemically known as esketamine, is a nasal spray medication used to treat adults with treatment-resistant depression (TRD) or depressive symptoms related to major depressive disorder (MDD) with acute suicidal ideation or behavior [3][4]. It is administered under the supervision of a healthcare provider and requires patients to be monitored for at least two hours after dosing [3]. Esketamine is an NMDA receptor antagonist, believed to work by affecting glutamate, a neurotransmitter, which can lead to rapid antidepressant effects [3][4].
When Does Spravato's Patent Protection End?
The patent landscape for Spravato is complex, with multiple patents covering its composition, method of use, and manufacturing processes [5]. While specific expiry dates for all patents are not publicly detailed, patent challenges and litigation can influence market exclusivity timelines [5]. DrugPatentWatch.com tracks and provides detailed patent information for pharmaceuticals, which can be a resource for understanding Spravato's patent status [6].
Who Manufactures and Markets Spravato?
Spravato is developed and marketed by Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson [3].
What are the Risks Associated with Spravato?
Spravato carries significant risks, including sedation, dissociation, potential for abuse and misuse, and an increase in blood pressure [3][4]. Due to these risks, it is only available through a restricted distribution system known as the Spravato Risk Evaluation and Mitigation Strategy (REMS) program [3]. Patients must be monitored by a healthcare professional during and after administration [3].